| Medical and Health Sciences | 2021-2025 | 371 | CA 12 | 99.92 |
| Biological Sciences | 2021-2025 | 236 | CA 8 | 99.77 |
| Dermatology | Lifetime | 41 | CA 2 | 99.73 |
| Immunology | Lifetime | 102 | CA 4 | 99.81 |
| Rheumatology | Lifetime | 779 | CA 40 | 96.00 |
| Instrumentation and Measurement Physics | Lifetime | 594 | CA 22 | 51.19 |
| Immunology | 2021-2025 | 10 | CA 1 | 99.73 |
| Dermatology | 2021-2025 | 18 | CA 2 | 99.76 |
| Rheumatology | 2021-2025 | 161 | CA 8 | 96.37 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 346 | CA 30 | 92.52 |
| Dermatology and Skin Diseases | Lifetime | 11 | CA 1 | 99.87 |
| Pharmaceutical studies and practices | Lifetime | 10 | CA 1 | 99.75 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 9 | CA 1 | 99.87 |
| Autoimmune Bullous Skin Diseases | Lifetime | 17 | CA 1 | 99.67 |
| Asthma and respiratory diseases | Lifetime | 118 | CA 9 | 99.64 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 77 | CA 8 | 99.35 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 416 | CA 39 | 98.88 |
| Allergic Rhinitis and Sensitization | Lifetime | 216 | CA 7 | 99.05 |
| Biosimilars and Bioanalytical Methods | Lifetime | 115 | CA 10 | 97.58 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 334 | CA 11 | 98.09 |
| Spondyloarthritis Studies and Treatments | Lifetime | 160 | CA 8 | 98.19 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 602 | CA 21 | 97.56 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 560 | CA 35 | 97.77 |
| Urticaria and Related Conditions | Lifetime | 438 | CA 9 | 96.42 |
| Food Allergy and Anaphylaxis Research | Lifetime | 517 | CA 25 | 96.70 |
| Mast cells and histamine | Lifetime | 471 | CA 22 | 95.61 |
| Complementary and Alternative Medicine Studies | Lifetime | 544 | CA 22 | 93.34 |
| Phosphodiesterase function and regulation | Lifetime | 277 | CA 11 | 92.14 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 392 | CA 16 | 82.95 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 5 | CA 1 | 99.81 |
| Dermatology and Skin Diseases | 2021-2025 | 10 | CA 1 | 99.75 |
| Pharmaceutical studies and practices | 2021-2025 | 5 | CA 1 | 99.42 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 21 | CA 2 | 98.87 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 47 | CA 5 | 99.17 |
| Asthma and respiratory diseases | 2021-2025 | 102 | CA 6 | 98.95 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 46 | CA 3 | 98.40 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 72 | CA 4 | 98.03 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 288 | CA 25 | 97.11 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 38 | CA 2 | 94.91 |
| Food Allergy and Anaphylaxis Research | 2021-2025 | 155 | CA 12 | 95.93 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 594 | CA 15 | 91.94 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 280 | CA 11 | 87.84 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 667 | CA 22 | 90.94 |
| Urticaria and Related Conditions | 2021-2025 | 311 | CA 11 | 89.35 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 943 | CA 34 | 82.60 |
| Mast cells and histamine | 2021-2025 | 403 | CA 8 | 77.74 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 846 | CA 19 | 59.99 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 565 | CA 17 | 59.47 |
| Transgenic Plants and Applications | 2021-2025 | 826 | CA 23 | 54.72 |
| Phosphodiesterase function and regulation | 2021-2025 | 296 | CA 11 | 50.91 |
